Cyclin-dependent kinase 2, 4, 6 and Aromatase (CDK2/4/6 + CYP19A1)

The combination of PF-06873600 and letrozole represents a multi-target therapeutic strategy rather than a single molecular entity. It involves the simultaneous inhibition of Cyclin-dependent kinases 2, 4, and 6 (CDK2/4/6) and the Aromatase enzyme (CYP19A1). PF-06873600 is an investigational small-molecule inhibitor designed to target CDK2 in addition to the traditional CDK4/6 targets, specifically to address resistance mechanisms in breast cancer where tumors upregulate the CDK2/Cyclin E1 pathway (Source: Pfizer Inc., ClinicalTrials.gov NCT03519126). Letrozole is a standard-of-care aromatase inhibitor that deprives hormone receptor-positive (HR+) tumors of estrogen, which is their primary growth driver (Source: PubChem CID 3902). This combination is primarily studied for the treatment of HR-positive, HER2-negative metastatic breast cancer. By blocking both the hormonal signaling and the core cell cycle machinery, the regimen aims to overcome endocrine resistance and provide more durable clinical responses (Source: ASCO Publications).

Other names

PF-06873600 and Letrozole combinationCDK2/4/6 and Aromatase inhibition therapyPF-06873600 plus letrozole

PF-06873600 acts as a potent and selective inhibitor of Cyclin-dependent kinases 2, 4, and 6, preventing the phosphorylation of the retinoblastoma (Rb) protein and halting the cell cycle at the G1/S transition (Source: Cancer Discovery, 2022). Letrozole is a non-steroidal aromatase inhibitor that binds to the heme group of the cytochrome P450 subunit of the aromatase enzyme (CYP19A1), preventing the conversion of androgens to estrogens and thereby reducing the hormonal stimulus for growth in estrogen-responsive breast cancer cells (Source: FDA Label for Femara).